Literature DB >> 4036659

Platelet MAO activity as a biological marker in subgroups of alcoholism.

A L von Knorring, M Bohman, L von Knorring, L Oreland.   

Abstract

In the Stockholm Adoption Study, two types of alcoholism, "Type I" and "Type II", have been identified on the basis of genetic predisposition. In the present study, this classification has been applied to a clinical sample. The two types of alcoholism were clinically clearly identifiable. Type I alcoholism was characterized by late onset and few social complications. Type II alcoholism was characterized by early onset, use and abuse not only of alcohol, but also of glue, cannabis, amphetamine and opioids, together with several social complications. The subjects with Type II alcoholism had also more alcoholism and depression among their first-degree relatives than the subjects with Type I alcoholism. Furthermore, the two types of alcoholism were separable by means of the biological marker - platelet MAO activity. While platelet MAO activity was normal in Type I alcoholics, as compared with healthy controls, it was clearly low in the Type II alcoholics. This subclassification of alcoholism seems to be of value in future studies concerning the etiology, epidemiology and treatment of alcoholism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4036659     DOI: 10.1111/j.1600-0447.1985.tb02570.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  30 in total

1.  Personality profile in type I alcoholism: long duration of alcohol intake and low serotonergic activity are predictive factors of anxiety proneness.

Authors:  K Berglund; C Fahlke; U Berggren; M Eriksson; J Balldin
Journal:  J Neural Transm (Vienna)       Date:  2006-02-06       Impact factor: 3.575

2.  Biological markers for increased risk of alcoholism and for quantitation of alcohol consumption.

Authors:  D W Crabb
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

3.  Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients.

Authors:  Ashwin A Patkar; Paolo Mannelli; Kathleen Peindl; Kevin P Hill; Raman Gopalakrishnan; Wade H Berrettini
Journal:  Psychopharmacology (Berl)       Date:  2006-01-17       Impact factor: 4.530

4.  Slipping through sky holes: Yurok body imagery in northern California.

Authors:  M K Ferreira
Journal:  Cult Med Psychiatry       Date:  1998-06

Review 5.  Personality as an intermediate phenotype for genetic dissection of alcohol use disorder.

Authors:  Lars Oreland; Gianvito Lagravinese; Simone Toffoletto; Kent W Nilsson; Jaanus Harro; C Robert Cloninger; Erika Comasco
Journal:  J Neural Transm (Vienna)       Date:  2017-01-04       Impact factor: 3.575

6.  Association of personality disorders with Type A and Type B alcoholics.

Authors:  Miriam Bottlender; Ulrich W Preuss; Michael Soyka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-27       Impact factor: 5.270

7.  Daidzin and its antidipsotropic analogs inhibit serotonin and dopamine metabolism in isolated mitochondria.

Authors:  W M Keung; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

8.  Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence.

Authors:  John H Krystal; Ismene L Petrakis; Diana Limoncelli; Susan Krasnicki Nappi; Louis Trevisan; Brian Pittman; Deepak C D'Souza; Raymond F Suckow
Journal:  Neuropsychopharmacology       Date:  2010-12-01       Impact factor: 7.853

9.  Severity of alcoholism in Indian males: Correlation with age of onset and family history of alcoholism.

Authors:  Pradeep R Johnson; Saira Banu; M V Ashok
Journal:  Indian J Psychiatry       Date:  2010-07       Impact factor: 1.759

Review 10.  Neurologic effects of alcoholism.

Authors:  I Diamond; R O Messing
Journal:  West J Med       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.